Results 131 to 140 of about 26,895 (263)

Impact of Time of Injection on the Efficacy and Safety of iGlarLixi Versus IDegAsp in Chinese People With Type 2 Diabetes: Exploratory Analysis of the Soli‐D Study

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims To compare the efficacy and safety of the fixed‐ratio combination of insulin glargine 100 U/mL plus lixisenatide (iGlarLixi) with premixed insulin degludec plus insulin aspart (IDegAsp) according to the injection time of IDegAsp. Materials and Methods The 24‐week, multicentre, randomised, open‐label Soli‐D study enrolled Chinese adults ...
Xin Li, Juan Wang, Tong Liu, Agustina Alvarez, Felipe Lauand, Lydie Melas‐Melt, Lei Kang, Qin Du, Ming Liu   +8 more
wiley   +1 more source

Chronic Kidney Disease in Patients With Type 2 Diabetes Mellitus: A Cross‐Sectional Population‐Based Study

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Chronic kidney disease (CKD) is a common complication of Type 2 diabetes that frequently co‐occurs with cardiovascular disease. We aimed to characterise CKD in adults with Type 2 diabetes, quantify its prevalence across severity levels and examine pharmacological treatment patterns and healthcare utilisation.
Neora Alterman, Yoel Toledano, Noga Fallach, Victor Gross, Galia Zacay   +4 more
wiley   +1 more source

Impact of sodium–glucose cotransporter 2 inhibitors on blood pressure

Vascular Health and Risk Management, 2016
James W Reed Morehouse School of Medicine, Atlanta, GA, USA Abstract: SGLT2 inhibitors are glucose-lowering agents used to treat type 2 diabetes mellitus (T2DM).
Reed JW
doaj  

Diabetes and menopause: A critical yet neglected intersection

Diabetic Medicine, EarlyView.
Isabell Haage, David Studer, Petra Stute, Lia Bally   +3 more
wiley   +1 more source

The Effects of Combined Antihypertensive and Antidiabetic Therapies on Cardiovascular Outcomes: A Systematic Review and Meta‐Analysis

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Hypertension and diabetes frequently coexist, yet the net clinical impact of intentionally combining antihypertensive (AHTN) and antidiabetic (ADA) therapies on cardiovascular (CV) outcomes is uncertain. Here we quantified the effects of AHTN and ADA co‐therapy on CV and blood pressure (BP)/heart rate (HR) outcomes.
Wan Chin Hsieh, Brandon Michael Henry, István Édes   +2 more
wiley   +1 more source

Prurigo pigmentosa in patient with diabetes on SGLT2 inhibitor. [PDF]

JAAD Case Rep
Khan T, Hirsch Y, McGivney R, Hoyer S.
europepmc   +1 more source

Impact of Sleeve Gastrectomy Versus Intensive Lifestyle Modifications With Obesity Management Medications on BMI Trajectory and Target Attainment: A Prospective Matched Cohort Study

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims To compare sleeve gastrectomy (SG) with intensive lifestyle modification combined with obesity management medications (ILM/OMMs) in adults with severe obesity, focusing on BMI trajectory, time to achieving clinically meaningful weight loss, and metabolic outcomes in a real‐world clinical setting.
Maria Francesca Russo, Giovanni Casella, Giulia Angelini, Sara Russo, James Casella‐Mariolo, Vito D'Andrea, Giulio Illuminati, Lidia Castagneto‐Gissey   +7 more
wiley   +1 more source

Bibliometric analysis of SGLT2 inhibitor treatment for diabetic kidney disease. [PDF]

Ren Fail
Hu D, Chen L, Mai R, Gao T, Guan B.
europepmc   +1 more source

Nationwide Real‐World Retrospective Study of Oral Semaglutide Use in Adults Living With Type 2 Diabetes in Finland

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aim This Finnish nationwide retrospective 'real‐world' study evaluated the effects of oral semaglutide on glycaemic control, body weight, lipid profile, and liver enzymes in adults living with type 2 diabetes (T2D) and naïve to any GLP‐1 receptor agonists in Finland.
Atte Vaden, Mari Lahelma, Lalli Nurmi, Eija Heikkilä, Hannu Vessari, Hanne Luoto, Tero Saukkonen, Leo Niskanen   +7 more
wiley   +1 more source

Cost‐Effectiveness of NT‐proBNP–Guided Cardiovascular Screening in Chinese Adults With Type 2 Diabetes: Real‐World Evidence From the Hong Kong Diabetes Biobank

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Heart failure (HF) is among the most costly and prevalent complications of type 2 diabetes (T2D), with annual incremental healthcare costs reaching US$12800 in Hong Kong. We evaluated the cost‐effectiveness of NT‐proBNP‐guided cardiovascular risk stratification to guide cardioprotective treatment. Materials and Methods We developed a four‐
Abby Q. Y. Li, Benjamin Yarnoff, Claudia H. T. Tam, Juliana C. N. Chan, Ronald C. W. Ma, Juliana N. M. Lui, Hong Kong Diabetes Biobank Study Group   +6 more
wiley   +1 more source